Background: Peanut flour is a high-protein, low-oil, powdered material prepared from roasted peanut seed. In addition to being a well-established food ingredient, peanut flour is also the active ingredient in peanut oral immunotherapy trials. Enzymatic hydrolysis was evaluated as a processing strategy to generate hydrolysates from peanut flour with reduced allergenicity. Methods: Soluble fractions of 10% (w/v) light roasted peanut flour dispersions were hydrolyzed with the following proteases: Alcalase (pH 8.0, 60°C), pepsin (pH 2.0, 37°C) or Flavourzyme (pH 7.0, 50°C) for 60 min. Western blotting, inhibition ELISA and basophil activation tests were used to examine IgE reactivity. Results: Western blotting experiments revealed the hydrolysates retained IgE binding reactivity and these IgE-reactive peptides were primarily Ara h 2 fragments regardless of the protease tested. Inhibition ELISA assays demonstrated that each of the hydrolysates had decreased capacity to bind peanut-specific IgE compared with nonhydrolyzed controls. Basophil activation tests revealed that all hydrolysates were comparable (p > 0.05) to nonhydrolyzed controls in IgE cross-linking capacity. Conclusions: These results indicate that hydrolysis of peanut flour reduced IgE binding capacity; however, IgE cross-linking capacity during hydrolysis was retained, thus suggesting such hydrolysates are not hypoallergenic.

Keywords:
Peanut flour, Peanut allergy, Proteolysis, Inhibition ELISA, Western blot, Basophil activation test, IgE cross-linking
1.
Astier C, Morisset M, Roitel O, Codreanu F, Jacquenet S, Franck P, Ogier V, Petit N, Proust B, Moneret-Vautrin DA, Burks AW, Bihain B, Sampson HA, Kanny G: Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. J Allergy Clin Immunol 2006;118:250-256.
2.
Burks AW, Williams LW, Connaughton C, Cockrell G, O'Brien TJ, Helm RM: Identification and characterization of a second major peanut allergen, Ara h II, with use of the sera of patients with atopic dermatitis and positive peanut challenge. J Allergy Clin Immunol 1992;90:962-969.
3.
Burks AW, Williams LW, Helm RM, Connaughton C, Cockrell G, Obrien T: Identification of a major peanut allergen, Ara-h-1, in patients with atopic-dermatitis and positive peanut challenges. J Allergy Clin Immunol 1991;88:172-179.
4.
Kleber-Janke T, Crameri R, Appenzeller U, Schlaak M, Becker WM: Selective cloning of peanut allergens, including profilin and 2S albumins, by phage display technology. Int Arch Allergy Immunol 1999;119:265-274.
5.
Rabjohn P, Helm EM, Stanley JS, West CM, Sampson HA, Burks AW, Bannon GA: Molecular cloning and epitope analysis of the peanut allergen Ara h 3. J Clin Invest 1999;103:535-542.
6.
Chen X, Zhuang Y, Wang Q, Moutsoglou D, Ruiz G, Yen SE, Dreskin SC: Analysis of the effector activity of Ara h 2 and Ara h 6 by selective depletion from a crude peanut extract. J Immunol Methods 2011;372:65-70.
7.
Porterfield HS, Murray KS, Schlichting DG, Chen X, Hansen KC, Duncan MW, Dreskin SC: Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants. Clin Exp Allergy 2009;39:1099-1108.
8.
Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW: Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009;124:292-300.
9.
Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW: A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011;127:654-660.
10.
Varshney P, Jones SM, Pons L, Kulis M, Steele PH, Kemper AR, Scurlock AM, Perry TT, Burks AW: Peanut oral immunotherapy (OIT) induces immunologic changes supporting the development of tolerance. J Allergy Clin Immunol 2010;125:AB59.
11.
Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW: Safety of a peanut oral immunotherapy protocol in children with peanut allergy. Allergy Clin Immunol 2009;124:286-291.
12.
Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE: Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol 2011;127:608-615.
13.
Cabanillas B, Pedrosa MM, Rodriguez J, Muzquiz M, Maleki SJ, Cuadrado C, Burbano C, Crespo JF: Influence of enzymatic hydrolysis on the allergenicity of roasted peanut protein extract. Int Arch Allergy Immunol 2012;157:41-50.
14.
Su GW, Ren JY, Yang B, Cui C, Zhao MM: Comparison of hydrolysis characteristics on defatted peanut meal proteins between a protease extract from Aspergillus oryzae and commercial proteases. Food Chem 2011;126:1306-1311.
15.
Zhao GL, Liu Y, Zhao MM, Ren JY, Yang B: Enzymatic hydrolysis and their effects on conformational and functional properties of peanut protein isolate. Food Chem 2011;127:1438-1443.
16.
Yu J, Ahmedna M, Goktepe I, Cheng H, Maleki S: Enzymatic treatment of peanut kernels to reduce allergen levels. Food Chem 2011;127:1014-1022.
17.
Thyagarajan A, Jones SM, Calatroni A, Pons L, Kulis M, Woo CS, Kamalakannan M, Vickery BP, Scurlock AM, Wesley Burks A, Shreffler WG: Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children. Clin Exp Allergy 2012;42:1197-1205.
18.
Adlernissen J: Determination of the degree of hydrolysis of food protein hydrolysates by trinitrobenzenesulfonic acid. J Agric Food Chem 1979;27:1256-1262.
19.
Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, Steele P, Kamilaris J, Vickery B, Burks AW: Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization, J Allergy Clin Immunol 2011;127:640-646.
20.
Kulis M, Macqueen I, Li Y, Guo R, Zhong XP, Burks AW: Pepsinized cashew proteins are hypoallergenic and immunogenic and provide effective immunotherapy in mice with cashew allergy. J Allergy Clin Immunol 2012;130:716-723.
21.
Mills ENC, Jenkins JA, Alcocer MJC, Shewry PR: Structural, biological, and evolutionary relationships of plant food allergens sensitizing via the gastrointestinal tract. Crit Rev Food Sci 2004;44:379-407.
22.
Breiteneder H, Radauer C: A classification of plant food allergens. J Allergy Clin Immunol 2004;113:821-830.
23.
Lehmann K, Schweimer K, Reese G, Randow S, Suhr M, Becker WM, Vieths S, Rosch P: Structure and stability of 2S albumin-type peanut allergens: implications for the severity of peanut allergic reactions. Biochem J 2006;395:463-472.
24.
Koppelman SJ, Hefle SL, Taylor SL, de Jong GAH: Digestion of peanut allergens Ara h 1, Ara h 2, Ara h 3, and Ara h 6: a comparative in vitro study and partial characterization of digestion-resistant peptides, Mol Nutr Food Res 2010;54:1711-1721.
25.
Kulis M, Chen X, Lew J, Wang Q, Patel OP, Zhuang Y, Murray KS, Duncan MW, Porterfield HS, Burks AW, Dreskin SC: The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice. Clin Exp Allergy 2012;42:326-336.
26.
Bogh KL, Kroghsbo S, Dahl L, Rigby NM, Barkholt V, Mills ENC, Madsen CB: Digested Ara h 1 has sensitizing capacity in Brown Norway Rats. Clin Exp Allergy 2009;39:1611-1621.
27.
Bannon GA, Ogawa T: Evaluation of available IgE-binding epitope data and its utility in bioinformatics. Mol Nutr Food Res 2006;50:638-644.
28.
Knol EF: Requirements for effective IgE cross-linking on mast cells and basophils. Mol Nutr Food Res 2006;50:620-624.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.